Enobia Pharma Inc.

Enobia Pharma Inc. is a biopharmaceutical company focused on developing innovative therapies for rare diseases by leveraging advanced scientific research to create impactful treatments. Enobia Pharma was founded in 1997 in Montreal, Canada, specializing in biopharmaceutical innovations. The company was acquired by Alexion Pharmaceuticals in December 2011 for USD 610 mn, with possible future milestone payments of USD 470 mn.

This acquisition reflects a strategic pivot towards enhancing its capabilities in rare disease therapeutics. The company has completed a total of five deals to date, demonstrating its active role in the biopharma sector. Enobia. com primarily serves as a premium domain name targeted at businesses in the technology, design, and creative sectors.

Its core offering is the domain name itself, marketed as a memorable and brandable asset ideal for entities seeking to establish a strong online presence. The platform emphasizes innovation, suggesting that the domain can help evoke a sense of creativity and modernity among its users. The company targets a global client base, offering the domain to entrepreneurs, startups, and established firms alike, looking to enhance their digital footprint. The domain is available for purchase at a price point of USD 4,199 or through a structured payment plan, making it accessible to a variety of businesses across different geographical markets.

Revenue generation for Enobia. com primarily occurs through the sale of its domain name, as well as additional services like logo creation offered with the purchase. Clients can engage with the company through a straightforward transaction process that includes immediate payment options or a payment plan that distributes the cost over several months. The payment structure is direct-to-consumer, allowing businesses and individuals to buy the domain outright or finance it with a stipulated monthly payment.

This model appeals to startups and small businesses who may prefer low initial outlays. Enobia. com’s revenue model is straightforward, with pricing set at USD 4,199, further supplemented by potential upsells such as logo design, enhancing the overall value proposition for clients. Following the acquisition by Alexion Pharmaceuticals in February 2012, Enobia Pharma is focused on expanding its product line and enhancing its market reach within the rare disease sector.

The recent funding will be utilized to support new product development and to facilitate entry into additional geographic markets. While specific upcoming product launches have not been detailed, the company aims to innovate within its therapeutic areas by leveraging its accumulated resources and expertise in biopharmaceuticals.